Copyright © 2009 Anne Nguyen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. M. Ladanyi, “Fusions of the SYT and SSX genes in synovial sarcoma,” Oncogene, vol. 20, no. 40, pp. 5755–5762, 2001. View at Publisher · View at Google Scholar · View at PubMed
2. A. Ferrari, A. Gronchi, M. Casanova, et al., “Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution,” Cancer, vol. 101, no. 3, pp. 627–634, 2004. View at Publisher · View at Google Scholar · View at PubMed
3. L. Guillou, J. Benhattar, F. Bonichon, et al., “Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis,” Journal of Clinical Oncology, vol. 22, no. 20, pp. 4040–4050, 2004. View at Publisher · View at Google Scholar · View at PubMed
4. S. Takenaka, T. Ueda, N. Naka, et al., “Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan,” Oncology Reports, vol. 19, no. 2, pp. 467–476, 2008.
5. B. Guadagnolo, G. Zagars, M. Ballo, et al., “Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy,” International Journal of Radiation Oncology, Biology, Physics, vol. 69, no. 4, pp. 1173–1180, 2007. View at Publisher · View at Google Scholar · View at PubMed
6. J. Terry, J. M. Lubieniecka, W. Kwan, S. Liu, and T. O. Nielsen, “Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models,” Clinical Cancer Research, vol. 11, no. 15, pp. 5631–5638, 2005. View at Publisher · View at Google Scholar · View at PubMed
7. T. W. Schulte, M. V. Blagosklonny, L. Romanova, et al., “Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway,” Molecular and Cellular Biology, vol. 16, no. 10, pp. 5839–5845, 1996.
8. W. Xu, E. Mimnaugh, M. F. N. Rosser, et al., “Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90,” The Journal of Biological Chemistry, vol. 276, no. 5, pp. 3702–3708, 2001. View at Publisher · View at Google Scholar · View at PubMed
9. P. Müller, P. Ceskova, and B. Vojtesek, “Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy,” The Journal of Biological Chemistry, vol. 280, no. 8, pp. 6682–6691, 2005. View at Publisher · View at Google Scholar · View at PubMed
10. M. Rahmani, E. Reese, Y. Dai, et al., “Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in ${\text{Bcr-Abl}}^{+}$ cells sensitive and resistant to STI571 (imatinib mesylate) in association with Down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change,” Molecular Pharmacology, vol. 67, no. 4, pp. 1166–1176, 2005. View at Publisher · View at Google Scholar · View at PubMed
11. M. Broemer, D. Krappmann, and C. Scheidereit, “Requirement of Hsp90 activity for I$\kappa$B kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-$\kappa$B activation,” Oncogene, vol. 23, no. 31, pp. 5378–5386, 2004. View at Publisher · View at Google Scholar · View at PubMed
12. J. Lewis, A. Devin, A. Miller, et al., “Disruption of Hsp96 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-$\kappa$B activation,” The Journal of Biological Chemistry, vol. 275, no. 14, pp. 10519–10526, 2000. View at Publisher · View at Google Scholar
13. P. Workman, “Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone,” Cancer Letters, vol. 206, no. 2, pp. 149–157, 2004. View at Publisher · View at Google Scholar · View at PubMed
14. L. Neckers and S. P. Ivy, “Heat shock protein 90,” Current Opinion in Oncology, vol. 15, no. 6, pp. 419–424, 2003.
15. D. B. Solit and G. Chiosis, “Development and application of Hsp90 inhibitors,” Drug Discovery Today, vol. 13, no. 1-2, pp. 38–43, 2008. View at Publisher · View at Google Scholar · View at PubMed
16. T. Ito, M. Ouchida, Y. Morimoto, et al., “Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo,” Cancer Letters, vol. 224, no. 2, pp. 311–319, 2005. View at Publisher · View at Google Scholar · View at PubMed
17. W. Kwan, J. Terry, S. Liu, M. Knowling, and T. O. Nielsen, “Effect of depsipeptide (NSC 630176), a histone deacetylase inhibitor, on human synovial sarcoma in vitro,” in Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO '05), Orlando, Fla, USA, May 2005, abstract 9039.
18. S. Liu, H. Cheng, W. Kwan, J. M. Lubieniecka, and T. O. Nielsen, “Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models,” Molecular Cancer Therapeutics, vol. 7, no. 6, pp. 1751–1761, 2008. View at Publisher · View at Google Scholar · View at PubMed
19. T. Kouzarides, “Chromatin modifications and their function,” Cell, vol. 128, no. 4, pp. 693–705, 2007. View at Publisher · View at Google Scholar · View at PubMed
20. P. A. Marks, T. Miller, and V. M. Richon, “Histone deacetylases,” Current Opinion in Pharmacology, vol. 3, no. 4, pp. 344–351, 2003. View at Publisher · View at Google Scholar
21. W. Gu and R. G. Roeder, “Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain,” Cell, vol. 90, no. 4, pp. 595–606, 1997. View at Publisher · View at Google Scholar
22. L.-F. Chen, W. Fischle, E. Verdin, and W. C. Greene, “Duration of nuclear NF-$\kappa$B action regulated by reversible acetylation,” Science, vol. 293, no. 5535, pp. 1653–1657, 2001. View at Publisher · View at Google Scholar · View at PubMed
23. X. Yu, Z. S. Guo, M. G. Marcu, et al., “Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228,” Journal of the National Cancer Institute, vol. 94, no. 7, pp. 504–513, 2002. View at Publisher · View at Google Scholar
24. S. Shankar and R. K. Srivastava, “Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis,” Advances in Experimental Medicine and Biology, vol. 615, pp. 261–298, 2008. View at Publisher · View at Google Scholar
25. T. Ito, M. Ouchida, S. Ito, et al., “SYT, a partner of SYT-SSX oncoprotein in synovial sarcomas, interacts with mSin3A, a component of histone deacetylase complex,” Laboratory Investigation, vol. 84, no. 11, pp. 1484–1490, 2004. View at Publisher · View at Google Scholar · View at PubMed
26. J. M. Lubieniecka, D. R. H. de Bruijn, L. Su, et al., “Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma,” Cancer Research, vol. 68, no. 11, pp. 4303–4310, 2008. View at Publisher · View at Google Scholar · View at PubMed
27. M. Rahmani, C. Yu, Y. Dai, et al., “Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells,” Cancer Research, vol. 63, no. 23, pp. 8420–8427, 2003.
28. P. George, P. Bali, S. Annavarapu, et al., “Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3,” Blood, vol. 105, no. 4, pp. 1768–1776, 2005. View at Publisher · View at Google Scholar · View at PubMed
29. H.-C. Huang, Y.-C. Liu, S.-H. Liu, B.-S. Tzang, and W.-C. Lee, “Geldanamycin inhibits trichostatin A-induced cell death and histone H4 hyperacetylation in COS-7 cells,” Life Sciences, vol. 70, no. 15, pp. 1763–1775, 2002. View at Publisher · View at Google Scholar
30. G. Yang, M. A. Thompson, S. J. Brandt, and S. W. Hiebert, “Histone deacetylase inhibitors induce the degradation of the $t$(8;21) fusion oncoprotein,” Oncogene, vol. 26, no. 1, pp. 91–101, 2007. View at Publisher · View at Google Scholar · View at PubMed
31. S. Shishodia and B. B. Aggarwal, “Nuclear factor-$\kappa$B: a friend or a foe in cancer?,” Biochemical Pharmacology, vol. 68, no. 6, pp. 1071–1080, 2004. View at Publisher · View at Google Scholar · View at PubMed
32. M. Karin, “Nuclear factor-$\kappa$B in cancer development and progression,” Nature, vol. 441, no. 7092, pp. 431–436, 2006. View at Publisher · View at Google Scholar · View at PubMed
33. A. Albini, R. Dell'Eva, R. Vené, et al., “Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-$\kappa$B and Akt as targets,” The FASEB Journal, vol. 20, no. 3, pp. 527–529, 2006. View at Publisher · View at Google Scholar · View at PubMed
34. S. T. Moran, K. Haider, Y. Ow, P. Milton, L. Chen, and S. Pillai, “Protein kinase C-associated kinase can activate NF$\kappa$B in both a kinase-dependent and a kinase-independent manner,” The Journal of Biological Chemistry, vol. 278, no. 24, pp. 21526–21533, 2003. View at Publisher · View at Google Scholar · View at PubMed
35. P. Francis, H. M. Namløs, C. Müller, et al., “Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential,” BMC Genomics, vol. 8, article 73, pp. 1–16, 2007. View at Publisher · View at Google Scholar · View at PubMed
36. M. W. Mayo, C. E. Denlinger, R. M. Broad, et al., “Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-$\kappa$B through the Akt pathway,” The Journal of Biological Chemistry, vol. 278, no. 21, pp. 18980–18989, 2003. View at Publisher · View at Google Scholar · View at PubMed
37. A. Kawai, N. Naito, A. Yoshida, et al., “Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1,” Cancer Letters, vol. 204, no. 1, pp. 105–113, 2004. View at Publisher · View at Google Scholar
38. T. Nojima, Y.-S. Wang, S. Abe, T. Matsuno, S. Yamawaki, and K. Nagashima, “Morphological and cytogenetic studies of a human synovial sarcoma xenotransplanted into nude mice,” Acta Pathologica Japonica, vol. 40, no. 7, pp. 486–493, 1990.
39. T.-C. Chou and P. Talalay, “Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors,” Advances in Enzyme Regulation, vol. 22, pp. 27–55, 1984. View at Publisher · View at Google Scholar
40. X. Wang, W. Ju, J. Renouard, J. Aden, S. A. Belinsky, and Y. Lin, “17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-$\kappa$B pathway,” Cancer Research, vol. 66, no. 2, pp. 1089–1095, 2006. View at Publisher · View at Google Scholar · View at PubMed
41. J. W. Pierce, R. Schoenleber, G. Jesmok, et al., “Novel inhibitors of cytokine-induced I$\kappa$B$\alpha$ phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo,” The Journal of Biological Chemistry, vol. 272, no. 34, pp. 21096–21103, 1997. View at Publisher · View at Google Scholar
42. J. M. Lubieniecka and T. O. Nielsen, “cDNA microarray-based translational research in soft tissue sarcoma,” Journal of Surgical Oncology, vol. 92, no. 4, pp. 267–271, 2005. View at Publisher · View at Google Scholar · View at PubMed
43. E. A. Ronnen, G. V. Kondagunta, N. Ishill, et al., “A phase II trial of 17-(allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma,” Investigational New Drugs, vol. 24, no. 6, pp. 543–546, 2006. View at Publisher · View at Google Scholar · View at PubMed
44. M. P. Goetz, D. Toft, J. Reid, et al., “Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer,” Journal of Clinical Oncology, vol. 23, no. 6, pp. 1078–1087, 2005. View at Publisher · View at Google Scholar · View at PubMed
45. Q. C. Ryan, D. Headlee, M. Acharya, et al., “Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma,” Journal of Clinical Oncology, vol. 23, no. 17, pp. 3912–3922, 2005. View at Publisher · View at Google Scholar · View at PubMed
46. W. M. Stadler, K. Margolin, S. Ferber, W. McCulloch, and J. A. Thompson, “A phase II study of depsipeptide in refractory metastatic renal cell cancer,” Clinical Genitourinary Cancer, vol. 5, no. 1, pp. 57–60, 2006. View at Publisher · View at Google Scholar
47. J. Terry, T. Saito, S. Subramanian, et al., “TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies,” American Journal of Surgical Pathology, vol. 31, no. 2, pp. 240–246, 2007. View at Publisher · View at Google Scholar · View at PubMed
48. H. S. Ghosh, J. V. Spencer, B. Ng, M. W. McBurney, and P. D. Robbins, “Sirt1 interacts with transducin-like enhancer of split-1 to inhibit nuclear factor $\kappa$B-mediated transcription,” Biochemical Journal, vol. 408, no. 1, pp. 105–111, 2007. View at Publisher · View at Google Scholar · View at PubMed